Tandem Diabetes Care, Inc.

LSE:0M0F Stock Report

Market Cap: US$2.4b

Tandem Diabetes Care Management

Management criteria checks 3/4

Tandem Diabetes Care's CEO is John Sheridan, appointed in Apr 2013, has a tenure of 11.75 years. total yearly compensation is $4.65M, comprised of 15.3% salary and 84.7% bonuses, including company stock and options. directly owns 0.083% of the company’s shares, worth $1.95M. The average tenure of the management team and the board of directors is 3.4 years and 4.5 years respectively.

Key information

John Sheridan

Chief executive officer

US$4.7m

Total compensation

CEO salary percentage15.3%
CEO tenure11.8yrs
CEO ownership0.08%
Management average tenure3.4yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Sheridan's remuneration changed compared to Tandem Diabetes Care's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$127m

Jun 30 2024n/an/a

-US$136m

Mar 31 2024n/an/a

-US$141m

Dec 31 2023US$5mUS$711k

-US$223m

Sep 30 2023n/an/a

-US$208m

Jun 30 2023n/an/a

-US$224m

Mar 31 2023n/an/a

-US$204m

Dec 31 2022US$6mUS$711k

-US$95m

Sep 30 2022n/an/a

-US$68m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

US$6m

Dec 31 2021US$6mUS$690k

US$16m

Sep 30 2021n/an/a

US$22m

Jun 30 2021n/an/a

US$7m

Mar 31 2021n/an/a

-US$25m

Dec 31 2020US$4mUS$600k

-US$34m

Sep 30 2020n/an/a

-US$49m

Jun 30 2020n/an/a

-US$42m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019US$11mUS$500k

-US$25m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$55m

Mar 31 2019n/an/a

-US$113m

Dec 31 2018US$2mUS$386k

-US$123m

Compensation vs Market: John's total compensation ($USD4.65M) is above average for companies of similar size in the UK market ($USD2.38M).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Sheridan (69 yo)

11.8yrs

Tenure

US$4,651,603

Compensation

Mr. John F. Sheridan has been President and Chief Executive Officer at Tandem Diabetes Care, Inc., since March 01, 2019 and served as its Chief Operating Officer and Executive Vice President since April 20...

Leadership Team

NamePositionTenureCompensationOwnership
John Sheridan
President11.8yrsUS$4.65m0.083%
$ 1.9m
Leigh Vosseller
Executive VP7yrsUS$1.25m0.051%
$ 1.2m
Susan Morrison
Executive VP & Chief Administrative Officer11.3yrsUS$1.25m0.038%
$ 892.3k
David Berger
Transitional Advisor1.1yrsUS$1.25m0.011%
$ 250.2k
Elizabeth Gasser
Executive Vice President and Chief Strategy & Product Officer3.6yrsUS$1.25m0.022%
$ 528.2k
Mark Novara
Executive VP & Chief Commercial Officer1.2yrsUS$2.72m0.030%
$ 697.4k
Jean-Claude Kyrillos
Executive VP & COOless than a yearno datano data
Rick Carpenter
Chief Technical Officer3.2yrsno data0.023%
$ 535.3k
Shannon Hansen
Executive VP3yrsno data0.020%
$ 481.6k
Tom Fox
Chief Human Resources Officer7.4yrsno datano data
Jordan Pinsker
Chief Medical Officer1.1yrsno datano data
James Leal
Chief Manufacturing Officer7.4yrsno data0.026%
$ 604.9k

3.4yrs

Average Tenure

56yo

Average Age

Experienced Management: 0M0F's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Sheridan
President5.6yrsUS$4.65m0.083%
$ 1.9m
Rebecca Robertson
Independent Chairwoman of the Board6yrsUS$222.78k0.014%
$ 336.8k
Kim Blickenstaff
Chair Emeritusless than a yearUS$198.78k0.28%
$ 6.6m
Christopher Twomey
Independent Director11.5yrsUS$200.95k0.036%
$ 858.9k
Dick Allen
Independent Director17.5yrsUS$214.67k0.059%
$ 1.4m
Peyton Howell
Independent Director4.4yrsUS$190.28k0.025%
$ 598.1k
Rajwant Sodhi
Independent Director4yrsUS$189.25k0.017%
$ 399.0k
Kathleen McGroddy-Goetz
Independent Director4.6yrsUS$189.25k0.021%
$ 482.5k
Myoungil Cha
Independent Director2.6yrsUS$176.55k0.012%
$ 271.2k
Joao Paulo Malagueira
Independent Director2.6yrsUS$177.55k0.012%
$ 271.2k

4.5yrs

Average Tenure

61.5yo

Average Age

Experienced Board: 0M0F's board of directors are considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 06:14
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tandem Diabetes Care, Inc. is covered by 37 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey JohnsonBaird
Travis SteedBarclays
Matt MiksicBarclays